CA2891201A1 - Protein slurp-1 for use in the treatment of ocular diseases - Google Patents
Protein slurp-1 for use in the treatment of ocular diseases Download PDFInfo
- Publication number
- CA2891201A1 CA2891201A1 CA2891201A CA2891201A CA2891201A1 CA 2891201 A1 CA2891201 A1 CA 2891201A1 CA 2891201 A CA2891201 A CA 2891201A CA 2891201 A CA2891201 A CA 2891201A CA 2891201 A1 CA2891201 A1 CA 2891201A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- slurp
- protein
- seq
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 35
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 29
- 208000022873 Ocular disease Diseases 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 31
- 208000015181 infectious disease Diseases 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 8
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 230000000699 topical effect Effects 0.000 claims description 11
- 229920002307 Dextran Polymers 0.000 claims description 7
- 229920000249 biocompatible polymer Polymers 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 4
- 229920001661 Chitosan Polymers 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- 229960003160 hyaluronic acid Drugs 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 229920001983 poloxamer Polymers 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920001710 Polyorthoester Polymers 0.000 claims description 2
- 229920002000 Xyloglucan Polymers 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 108010054442 polyalanine Proteins 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 claims 1
- 102100038583 Secreted Ly-6/uPAR-related protein 1 Human genes 0.000 abstract description 2
- 101710127389 Secreted Ly-6/uPAR-related protein 1 Proteins 0.000 abstract 1
- 230000035876 healing Effects 0.000 description 29
- 235000018102 proteins Nutrition 0.000 description 18
- 206010052428 Wound Diseases 0.000 description 16
- 208000027418 Wounds and injury Diseases 0.000 description 16
- 210000004087 cornea Anatomy 0.000 description 16
- 230000029663 wound healing Effects 0.000 description 15
- 230000000694 effects Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 9
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 201000001999 mal de Meleda Diseases 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 8
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 102100038579 Secreted Ly-6/uPAR domain-containing protein 2 Human genes 0.000 description 6
- 101710171964 Secreted Ly-6/uPAR domain-containing protein 2 Proteins 0.000 description 6
- 241000270295 Serpentes Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000002581 neurotoxin Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 231100000618 neurotoxin Toxicity 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000007547 defect Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 206010055665 Corneal neovascularisation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004873 anchoring Methods 0.000 description 3
- 201000000159 corneal neovascularization Diseases 0.000 description 3
- 230000004453 corneal transparency Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 102100022002 CD59 glycoprotein Human genes 0.000 description 2
- 208000028006 Corneal injury Diseases 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 2
- 101001065559 Homo sapiens Lymphocyte antigen 6D Proteins 0.000 description 2
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 2
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 2
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- SDZRWUKZFQQKKV-JHADDHBZSA-N cytochalasin D Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@H]\3[C@]2([C@@H](/C=C/[C@@](C)(O)C(=O)[C@@H](C)C/C=C/3)OC(C)=O)C(=O)N1)=C)C)C1=CC=CC=C1 SDZRWUKZFQQKKV-JHADDHBZSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 230000002197 limbic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 108010055167 CD59 Antigens Proteins 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 208000036086 Chromosome Duplication Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 206010015911 Eye burns Diseases 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 description 1
- 101000664418 Homo sapiens Secreted Ly-6/uPAR-related protein 1 Proteins 0.000 description 1
- 101000638886 Homo sapiens Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 102100032127 Lymphocyte antigen 6D Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000532838 Platypus Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010042352 Urokinase Plasminogen Activator Receptors Proteins 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 102000051442 human CD59 Human genes 0.000 description 1
- 102000049578 human SLURP1 Human genes 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940037201 oris Drugs 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229920001187 thermosetting polymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Cell Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12196007.4 | 2012-12-07 | ||
| EP12196007.4A EP2740485B1 (en) | 2012-12-07 | 2012-12-07 | Protein slurp-1 for use in the treatment of ocular diseases |
| PCT/EP2013/075981 WO2014087022A1 (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2891201A1 true CA2891201A1 (en) | 2014-06-12 |
Family
ID=47297008
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2891201A Abandoned CA2891201A1 (en) | 2012-12-07 | 2013-12-09 | Protein slurp-1 for use in the treatment of ocular diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10098925B2 (https=) |
| EP (1) | EP2740485B1 (https=) |
| JP (1) | JP6335188B2 (https=) |
| KR (1) | KR20150108351A (https=) |
| CN (1) | CN105188731B (https=) |
| AU (1) | AU2013353957B2 (https=) |
| BR (1) | BR112015013215A2 (https=) |
| CA (1) | CA2891201A1 (https=) |
| CL (1) | CL2015001520A1 (https=) |
| EA (1) | EA201591095A1 (https=) |
| IL (1) | IL239078A0 (https=) |
| MX (1) | MX2015006779A (https=) |
| SG (2) | SG10201705592YA (https=) |
| WO (1) | WO2014087022A1 (https=) |
| ZA (1) | ZA201503747B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
| EP3689327B1 (fr) * | 2019-01-24 | 2025-03-12 | Organes Tissus Régénération Réparation Remplacement | Composition pharmaceutique dans le traitement de lésions pulmonaires |
| CN114601915B (zh) * | 2022-03-25 | 2023-04-07 | 四川大学华西医院 | Slurp1蛋白在制备预防或治疗皮肤弹性纤维疾病的药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1257184B (it) | 1992-12-22 | 1996-01-10 | Applied Research Systems | Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale |
| AU2004229237B2 (en) * | 2003-04-16 | 2009-06-04 | Merck Serono Sa | Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction |
| US20100303788A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases |
| CA2806143A1 (en) * | 2010-07-30 | 2012-02-02 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H | Drug delivery devices and growth factor formulations for accelerated wound healing |
| EP3848055A1 (en) * | 2011-06-03 | 2021-07-14 | Ophidion Inc. | Compositions and methods for transport across the blood brain barrier |
| US9132193B2 (en) * | 2012-11-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of Slurp1 as an imunomodulatory molecule in the ocular surface |
| CA2890424C (en) * | 2012-11-08 | 2020-11-17 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
| EP2740485B1 (en) * | 2012-12-07 | 2018-10-31 | Brightpulse Holding LTD. | Protein slurp-1 for use in the treatment of ocular diseases |
-
2012
- 2012-12-07 EP EP12196007.4A patent/EP2740485B1/en not_active Not-in-force
-
2013
- 2013-12-09 CA CA2891201A patent/CA2891201A1/en not_active Abandoned
- 2013-12-09 WO PCT/EP2013/075981 patent/WO2014087022A1/en not_active Ceased
- 2013-12-09 MX MX2015006779A patent/MX2015006779A/es unknown
- 2013-12-09 CN CN201380064175.2A patent/CN105188731B/zh not_active Expired - Fee Related
- 2013-12-09 SG SG10201705592YA patent/SG10201705592YA/en unknown
- 2013-12-09 EA EA201591095A patent/EA201591095A1/ru unknown
- 2013-12-09 KR KR1020157015595A patent/KR20150108351A/ko not_active Withdrawn
- 2013-12-09 BR BR112015013215A patent/BR112015013215A2/pt not_active IP Right Cessation
- 2013-12-09 US US14/650,277 patent/US10098925B2/en not_active Expired - Fee Related
- 2013-12-09 AU AU2013353957A patent/AU2013353957B2/en not_active Ceased
- 2013-12-09 SG SG11201503658XA patent/SG11201503658XA/en unknown
- 2013-12-09 JP JP2015546050A patent/JP6335188B2/ja not_active Expired - Fee Related
-
2015
- 2015-05-26 ZA ZA2015/03747A patent/ZA201503747B/en unknown
- 2015-05-28 IL IL239078A patent/IL239078A0/en unknown
- 2015-06-04 CL CL2015001520A patent/CL2015001520A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL239078A0 (en) | 2015-07-30 |
| EP2740485A1 (en) | 2014-06-11 |
| SG11201503658XA (en) | 2015-06-29 |
| CN105188731B (zh) | 2019-02-05 |
| SG10201705592YA (en) | 2017-08-30 |
| BR112015013215A2 (pt) | 2018-02-06 |
| CN105188731A (zh) | 2015-12-23 |
| EP2740485B1 (en) | 2018-10-31 |
| ZA201503747B (en) | 2016-03-30 |
| AU2013353957A1 (en) | 2015-05-28 |
| CL2015001520A1 (es) | 2016-05-20 |
| US20150320831A1 (en) | 2015-11-12 |
| JP2016502558A (ja) | 2016-01-28 |
| EA201591095A1 (ru) | 2015-11-30 |
| KR20150108351A (ko) | 2015-09-25 |
| AU2013353957B2 (en) | 2018-05-17 |
| WO2014087022A1 (en) | 2014-06-12 |
| MX2015006779A (es) | 2015-10-29 |
| US10098925B2 (en) | 2018-10-16 |
| JP6335188B2 (ja) | 2018-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2508196B1 (en) | Use of PEDF-derived polypeptides for promoting stem cells proliferation and wound healing | |
| RU2705211C2 (ru) | Композиция и способ лечения кожных рубцов | |
| US9345744B2 (en) | Peptide-based collagen modulators for wound healing and tissue repair | |
| JP6416240B2 (ja) | 種々の皮膚症状の処置に有用なヒトｃ−ｘ−ｃケモカイン由来テトラペプチド | |
| EP3986430B1 (en) | Methods of promoting vasculogenesis | |
| EP3347034B1 (en) | A hepatocyte growth factor receptor (hgfr)-binding composition for use in a method of treating corneal haze or scarring | |
| US10098925B2 (en) | Protein SLURP-1 for use in the treatment of ocular diseases | |
| Rao et al. | Hyaluronic acid sustains platelet stability with prolonged growth factor release and accelerates wound healing by enhancing proliferation and collagen deposition in diabetic mice | |
| CN111420023B (zh) | 含i型胶原和透明质酸的复合物及制备和用途 | |
| JP2023550661A (ja) | ドライアイ治療用薬の調製におけるｐ５５ｐｉｋ阻害剤の応用 | |
| Robinson et al. | Proteolytic processing of connective tissue growth factor in normal ocular tissues and during corneal wound healing | |
| Park et al. | Biomechanic, proteomic and miRNA transcriptional changes in the trabecular meshwork of primates injected with intravitreal triamcinolone | |
| Rieck et al. | Human recombinant bFGF stimulates corneal endothelial wound healing in rabbits | |
| CN115991758A (zh) | 一种促进糖尿病创面愈合的珍珠粉多肽及其应用 | |
| Moysenovich et al. | Recombinant spidroin films attenuate individual markers of glucose induced aging in NIH 3T3 fibroblasts | |
| CN111346217B (zh) | 多肽tdl23的新用途 | |
| CN111632127B (zh) | 短链胜肽组合物及其于皮肤保护的用途 | |
| EP1586324B1 (en) | Use of the pentapeptide PHSRN in ophthalmic formulations | |
| WO2020037714A1 (zh) | Trail突变体在制备治疗痤疮药物中的应用及一种制剂 | |
| TWI693941B (zh) | 短鏈胜肽組合物及其於皮膚保護之用途 | |
| Mao et al. | Bioactive thermoresponsive fibronectin–Pluronic F127 hydrogel for sustained ocular delivery with corneal regeneration and anti-inflammatory effects | |
| Elkhawaga et al. | Assessment of Corneal Epithelial Healing Rate after Pterygium Excision When Using 2% Hyaluronic Acid. | |
| HK40073737A (en) | Methods of promoting vasculogenesis | |
| HK40073737B (en) | Methods of promoting vasculogenesis | |
| HK1073071B (en) | Methods and compositions for the promotion of hair growth utilizing actin binding peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20191210 |